|
Press Releases |
|
|
|
Thursday, June 2, 2022 |
|
Connected Transactions Involving Subscription by Vivo Suzhou Fund and Centerlab for TOT BIOPHARM Shares |
On June 1, 2022, TOT BIOPHARM (Stock code: 1875. HK) announced that the company entered into a Share Subscription Agreement with VIVO Suzhou Fund and Centerlab. Pursuant to the agreement, Vivo Suzhou Fund and Centerlab agreed to subscribe for 116,250,000 and 33,750,000 shares of TOT BIOPHARM more info >> |
|
Wednesday, June 1, 2022 |
|
维梧苏州基金及晟德大药厂认购东曜药业股份 |
东曜药业(股票代码:1875.HK)宣布公司与维梧苏州基金及晟德大药厂订立股份认购协议。根据协议,维梧苏州基金与晟德大药厂将分别认购东曜药业配售股份116,250,000股及33,750,000股,认购价每股 3.15港元(依据过往5个交易日溢价发行),合共150,000,000股,占本公告日期公司已发行股本约24.38%。 more info >> |
|
維梧蘇州基金及晟德大藥廠認購東曜藥業股份 |
東曜藥業(股票代碼:1875.HK)宣佈公司與維梧蘇州基金及晟德大藥廠訂立股份認購協議。根據協議,維梧蘇州基金與晟德大藥廠將分別認購東曜藥業配售股份116,250,000股及33,750,000股,認購價每股 3.15港元(依據過往5個交易日溢價發行),合共150,000,000股,占本公告日期公司已發行股本約24.38%。 more info >> |
|
Connected Transactions Involving Subscription by Vivo Suzhou Fund and Centerlab for TOT BIOPHARM Shares |
TOT BIOPHARM (Stock code: 1875. HK) announced that the company entered into a Share Subscription Agreement with VIVO Suzhou Fund and Centerlab. Pursuant to the agreement, Vivo Suzhou Fund and Centerlab agreed to subscribe for 116,250,000 and 33,750,000 shares of TOT BIOPHARM more info >> |
|
Friday, August 13, 2021 |
|
東曜藥業2021年中期營業收入大幅增長78%至人民幣2,313萬元 |
東曜藥業股份有限公司(「東曜藥業」或「公司」;股票代碼:1875.HK)- 專注於創新型腫瘤藥物及療法開發和商業化的生物製藥公司,今天欣然宣佈其截至2021年6月30日止6個月未經審核中期業績。 more info >> |
|
TOT BIOPHARM 2021 Interim Revenue Surges 78% to RMB23.13 million |
TOT BIOPHARM International Company Limited ("TOT BIOPHARM" or the "Group"; stock code: 1875.HK), a biopharmaceutical company dedicated to developing and commercializing innovative oncology drugs and therapies, announced today its unaudited interim results for the six months ended 30 June 2021. more info >> |
|
Wednesday, March 24, 2021 |
|
東曜藥業宣佈2020年多項重點抗腫瘤藥物進入關鍵臨床階段 |
東曜藥業股份有限公司(「東曜藥業」或「公司」;股票代碼:1875.HK)- 專注於創新型腫瘤藥物及療法的臨床階段生物製藥公司,今天欣然宣佈其截至2020年12月31日止年度(「年內」)之經審核全年業績。 more info >> |
|
TOT BIOPHARM Announces A Number of Key Anti-Tumor Drugs Have Entered the Pivotal Clinical Stage in 2020 |
TOT BIOPHARM International Company Limited ("TOT BIOPHARM" or the "Company"; stock code: 1875.HK), a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative oncology drugs and therapies, announced today its audited annual results for the year ended 31 December 2020. more info >> |
|
Friday, October 16, 2020 |
|
东曜药业股份有限公司完善公司管理架构 推动战略发展升级 |
东曜药业股份有限公司(「东曜药业」或「公司」;股票代码:1875.HK)今日欣然宣布委任执行董事黄纯莹女士(「黄女士」)为董事会副主席,辞任总经理一职;同时宣布委任执行董事兼首席科学官刘军博士(「刘博士」)为公司首席执行官,并不再兼任首席运营官及副总经理职务。 more info >> |
|
東曜藥業股份有限公司完善公司管理架構 推動戰略發展升級 |
東曜藥業股份有限公司(「東曜藥業」或「公司」;股票代碼:1875.HK)今日欣然宣佈委任執行董事黃純瑩女士(「黃女士」)為董事會副主席,辭任總經理一職;同時宣佈委任執行董事兼首席科學官劉軍博士(「劉博士」)為公司首席執行官,並不再兼任首席運營官及副總經理職務。 more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
華住公佈2024年第一季度財報 收入增長17.8%优于预期
May 17, 2024 22:39 HKT/SGT
|
|
|
H World Group Limited Reports Q1 2024 Financial Results with 17.8% Revenue Growth, Surpassing Expectation
May 17, 2024 22:29 HKT/SGT
|
|
|
Top executives from SDAIA, Saudi Aramco, Almarai, Saudi Pro League & many others coming to speak at Smart Data & AI Summit
May 17, 2024 20:09 HKT/SGT
|
|
|
卓悦集团附属公司与“湖南广电芒果超媒”旗下“快乐购”签署战略合作备忘录
May 17, 2024 20:00 HKT/SGT
|
|
|
卓悅集團附屬公司與「湖南廣電芒果超媒」旗下「快樂購」簽署戰略合作備忘錄
May 17, 2024 19:43 HKT/SGT
|
|
|
Raytech Holding: Making Nasdaq Debut as It Pioneers Personal Care Electrical Appliances in a Booming Market
May 17, 2024 18:00 HKT/SGT
|
|
|
中信国际电讯CPC守正创新 AI创新方案喜迎两大奖
May 17, 2024 17:04 HKT/SGT
|
|
|
中信國際電訊CPC守正創新 AI創新方案喜迎兩大獎
May 17, 2024 16:55 HKT/SGT
|
|
|
CITIC Telecom CPC's Innovation Excellence Honored with 2 Innovation Awards
May 17, 2024 16:37 HKT/SGT
|
|
|
London Climate Technology Show 2024 Returns For Third Edition at ExCeL London
May 17, 2024 15:48 HKT/SGT
|
|
|
Sri Trang (SET: STA) announces delivery of EUDR rubber to customers
May 17, 2024 15:00 HKT/SGT
|
|
|
Sri Trang (SET: STA) announces delivery of EUDR rubber to customers
May 17, 2024 15:00 HKT/SGT
|
|
|
富士通、論理推論を可能とする大規模言語モデルの研究開発が「GENIAC」に採択
May 17, 2024 14:00: JST
|
|
|
Fujitsu chosen for GENIAC project, starts development of large language models for logical reasoning
May 17, 2024 14:03 JST
|
|
|
NEC Leverages RISE with SAP and AI to Build Business AI in Move to the Cloud
May 17, 2024 11:19 JST
|
|
|
|
More News >> |
|
|
|
|
|